HOME > COMMENTARY
COMMENTARY
-
Current Promising Drug Candidates with a New Mode of Action
August 8, 2011
-
Consumption Tax Hike to Go With Measures to Increase Efficiency of Soc. Security System
July 18, 2011
-
Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan
July 4, 2011
-
Era of Competition Dawns in Market for AD Treatments
June 27, 2011
-
Will Dialogue between PSJ, JAMS Accelerate Development of Switch OTC Drugs?
June 20, 2011
-
Return to Full-bore Growth Strategy Risky for Taiyo Pharm
June 13, 2011
-
Why the Same Mistake Repeated? -MSD's Promotion Code Violations
June 6, 2011
-
GE Makers to Make Difficult Decision on Actos Generics due to Combination Patent
June 6, 2011
-
Effects of Changes to Accelerate Approval to Be Seen from November
May 30, 2011
-
Japan's Most Admired Pharma Companies in 2010
April 4, 2011
-
Will New Disclosure GL Promote Industry-Academia Alliances?
March 28, 2011
-
Use of Generics by Welfare Recipients
March 7, 2011
-
Wholesalers' Profits Drop Sharply Putting Premium for New Drug Development in Peril
February 21, 2011
-
Safety Measures Based on Common Medical Knowledge Questioned by Court: Iressa Affair
February 21, 2011
-
Recent Topics in Promising Anticancer Therapeutics
January 17, 2011
-
Development Race for Oral Anticoagulants Entering Final Stretch
October 11, 2010
-
How to Eliminate Concerns about Safety of Liovel
October 4, 2010
-
Will It Be Possible to Eliminate Unnecessary Equivalence Studies for Generics?
September 20, 2010
-
Big Pharma Losing Flagships within a Few Years and Shifting Paradigm
September 13, 2010
-
Prior Assessment System Is One Step Forward to Quicker NDA Review
August 2, 2010
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…